Providers see hospital-at-home growth potential in cancer care
Mayo Clinic, Mount Sinai and Huntsman Cancer Insitute are delivering services from chemotherapy to imaging in cancer patients’ homes.
Related Articles
Perceived Stressed Associated With Symptom Burden in People With Fibromyalgia
Endocrinological stress indicators were not associated with perceived stress, which was related to symptom severity.
Crisis in CRISPR world, RFK Jr.’s promises, and a novel non-opioid pain drug
Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he’s confirmed to lead the Department of Health and Human…
Meteorin-like alleviates hepatic steatosis by regulating hepatic triglyceride secretion and fatty acid oxidation
Triglyceride (TG) secretion from the liver is critical in NAFLD progression and liver physiology, but the mechanism is not entirely clear. Song et al. show that…
OpenAI now reveals more of its o3-mini model’s thought process | TechCrunch
OpenAI is changing the way its newest AI model, o3-mini, communicates its step-by-step “thought” process.
Why Teladoc Health is Acquiring Catapult Health for $65M – MedCity News
Teladoc Health’s acquisition of Catapult Health will add “another channel” to funnel patients into Teladoc’s chronic care programs, according to one healthcare expert.
Global Cost of Renewables to Continue Falling in 2025 as China Extends Manufacturing Lead: BloombergNEF | BloombergNEF
New York/ London, February 6, 2025 – The cost of clean power technologies such as wind, solar and battery technologies are expected to fall further…
Has Legalized Cannabis Led to a Surge in Schizophrenia Cases?
A new Canadian study shows a tripling of schizophrenia cases linked to cannabis use disorder since the country legalized it.
Cold-Related Deaths in the US, 1999-2022
This study examines trends in cold-related mortality overall and by demographic characteristics between 1999 and 2022 in the US.
Reflections on the Successes of Pediatric Vaccines
This Viewpoint discusses the importance of early and continued vaccine use in the US.
Trump’s pick for science adviser is a rarity among his nominees — he’s not controversial
Unlike most previous OSTP directors, Michael Kratsios is not an esteemed scientist or engineer, but he has earned mostly positive reviews.